About KemPharm
KemPharm is a company based in Celebration (United States) founded in 2006 by Christal Mickle. KemPharm has raised $25.75 million across 11 funding rounds from investors including Deerfield. The company has 36 employees. KemPharm operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Celebration, United States
- Employees 36
- Founders Christal Mickle
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website kempharm.com
- Social LinkedIn X Facebook
- Annual Revenue$28.65 M (USD)116as on Dec 31, 2021
- Net Profit-$8.56 M (USD)33as on Dec 31, 2021
- EBITDA$7.73 M (USD)238as on Dec 31, 2021
- Total Equity Funding$25.75M (USD)
in 11 rounds
- Latest Funding Round$31.48M (USD), Post-IPO
Jan 2021
- Investors
- Employee Count36
Funding Insights of KemPharm
KemPharm has successfully raised a total of $25.75M across 11 strategic funding rounds. The most recent funding activity was a Post-IPO round of $31.48 million completed in January 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $25.75M
- Total Rounds 11
- Last Round Post-IPO — $31.48M
- First Round $647,200
(May 2008)
- Investors Count 1
Latest 10 of 11 funding rounds of KemPharm with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2021 | $31.48M | Post-IPO | – | – | – |
| Jan 2020 | $3.04M | Post-IPO | – | – | – |
| Dec 2019 | $71.42M | Post-IPO | – | – | – |
| Feb 2016 | $86.25M | Post-IPO | – | – | |
| Mar 2015 | $4M | Series C | – | – | – |
| Jun 2014 | $10M | Series C | – | – | |
| Jun 2014 | $15M | Debt – Conventional | – | – | |
| May 2013 | $762,000 | Series B | – | – | – |
| Jun 2011 | $6.85M | Series B | – | – | – |
| Aug 2009 | $3.49M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in KemPharm
KemPharm has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Deerfield.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States |
Investor details for KemPharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of KemPharm
27 people are tracked at KemPharm (14 in leadership, 5 in board & advisors, 8 in team); the tracked headcount is 36.
| Name | Role | Group |
|---|---|---|
Christal Mickle | Co-Founder | Leadership |
R. Laduane Clifton | Chief Financial Officer, Secretary and Treasurer | Leadership |
Joshua Schafer | Chief Commercial Officer & EVP, Business Development | Leadership |
Abbi M. | Vp, Legal Affairs | Leadership |
Sven Guenther | Chief Scientific Officer | Leadership |
Mark Meier | Sr. Director, Marketing And Thought Leader Liaison | Leadership |
David Rowe Wood | Head Of Field Medical Affairs | Leadership |
Melissa Beatty | Executive Director, Patient Services | Leadership |
Louise Himmelstrup | Vice President EU Regulatory Affairs | Leadership |
Adam Smith | Vice President, Business Development And Commercial Operations | Leadership |
Robyn Shields | Director Of Financial Reporting | Leadership |
Laduane Clifton | Chief Financial Officer, Secretary And Treasurer | Leadership |
Sanjib Bera | VP Drug Discovery | Leadership |
Adrian Quartel | Chief Medical Officer | Leadership |
Joseph B. Saluri | Board Member | Board & advisors |
David S. Tierney | Board Member | Board & advisors |
Christopher Posner | Board Member | Board & advisors |
Matthew R. Plooster | Chairman | Board & advisors |
Tamara A. Favorito | Board Member | Board & advisors |
Rene A. Braeckman | SVP, Clinical Development | Team |
7 more people are available in the full profile.
Complete people profiles for KemPharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of KemPharm
4 dated milestones of KemPharm across 15 years, from founding to its latest funding, stage changes and deals.
- Founded KemPharm is founded.
- Funding First funding round of $647K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $31.5M.
Competitors of KemPharm
KemPharm operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. | |
| herontx.com | 1983 | Redwood, United States | $32.14M | 21 | Reformulated injectables for chemotherapy side effects and pain are developed. | |
| painreform.com | 2007 | Herzliya, Israel | $12M | – | Pain treatment products are developed through reformulation technologies. | |
| trevena.com | 2007 | Philadelphia, United States | $203M | 35 | GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | |
| satsumarx.com | 2016 | San Francisco, United States | $74.13M | 24 | Therapeutics for migraine treatment are developed using nasal delivery. | |
| concentricanalgesics.com | 2014 | San Francisco, United States | $85.46M | – | Developer of platform for developing pro-drugs |
Detailed competitors of KemPharm
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of KemPharm
The website of KemPharm (kempharm.com) receives about 2.9K visits a month and ranks #4,695,990 among all websites worldwide, #5,574 in Biotechnology and Pharmaceuticals.
- Monthly visits2.9K
▼ 21.4% vs previous month
- Unique visitors1.5K
per month
- Global rank#4,695,990
among all websites
- Category rank#5,574
Health · Biotechnology and Pharmaceuticals
- Bounce rate37%
- Pages per visit1.7
- Average visit12 sec
- DevicesDesktop 34% · Mobile 66%
Websites whose visitors overlap most with KemPharm. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| proteostasis.com | 100% | – | – | View details | |
movantikhcp.com | movantikhcp.com | 68% | – | – | – |
iowacityhospice.org | iowacityhospice.org | 62% | – | #5,494,355 | – |
Latest news on Kempharm
Complete news archive for KemPharm
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to KemPharm
10 companies that operate in the same segment as KemPharm (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about KemPharm
KemPharm was founded in 2006 and raised its 1st funding round 2 years after it was founded.
KemPharm is headquartered in Celebration, United States. It is registered at Celebration, Florida, United States.
KemPharm is a funded company, having raised a total of $25.75M across 11 funding rounds to date. The company's 1st funding round was a Series A of $3.49M, raised on May 2008.
KemPharm has 36 employees.
Annual revenue of KemPharm is $28.65M as on Dec 31, 2021.
KemPharm was founded in 2006 and is based in Celebration, United States, within the pharmaceutical sector. Proprietary prodrugs are discovered and developed through the Ligand Activated Therapy (LAT) platform to refine attributes of existing medications. The pipeline includes KP201APAP, a hydrocodone prodrug paired with acetaminophen, as well as candidates targeting ADHD with methylphenidate and multiple CNS disorders with quetiapine. Operations emphasize new molecular entities for improved drug performance.
KemPharm's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
KemPharm has 1 investor. Key investors include Deerfield.